November 22nd 2024
Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Physician responds to Chester Valley concerns
December 1st 2006EDITOR'S NOTE: Dr. Leon Kircik is replying to a clarification from Chester Valley Pharmaceuticals that ran in our November issue on an article in the October issue, "Vehicles often drive treatment of difficult ailments." Atopiclair is Chester Valley Pharmaceutical's product. While Dr. Kircik was not the author of the article (he was interviewed by Senior Staff Correspondent John Jesitus) he did see the article before it went to press for his approval, as is Dermatology Times' standard practice with clinical articles.
Long-suffering rosacea patient asks, 'Doctors, please listen to your patients'
December 1st 2006In his Guest Commentary "Managing rosacea; practitioners discuss trends" (September 2006), Dr. William Baum presents his findings after moderating advisory panels across the country consisting of specialists talking about the many facets of rosacea.
New study shows betamethasone's effectiveness in treating psoriasis
November 7th 2006Bochum, Germany-Results of a recent study conducted at Ruhr University here suggest that the corticosteroid betamethasone is more effective for treatment of intertriginous psoriasis than is pimecrolimus or calcipotriol.
Indoor tanning restrictions top priority for AAD
November 1st 2006On behalf of the American Academy of Dermatology, I would like to respond to a letter to the editor from Michael Franzblau, M.D., regarding the Academy's efforts to restrict access to indoor tanning equipment. ("Cannot fathom AAD/AADA indifference toward indoor tanning regs," September, 2006). The letter's criticisms are not supported by the facts, and I appreciate the opportunity to set the record straight.
How best to communicate with ...
November 1st 2006"Usually, when kids go to the clinic, especially if they're little, they get so many vaccinations that when one takes off their clothes, they think they're getting a shot," explains Papri Sarkar, M.D., a third-year resident in Harvard's dermatology training program. "Also, I try to avoid using gloves unless they're clinically necessary."
Childhood cutaneous T-cell lymphomas on rise, experts say
November 1st 2006National report - The two forms of cutaneous T-cell lymphomas (CTCL), mycosis fungoides (MF) and S?zary syndrome, are reported to arise more often in adults than in children. But the incidence of cutaneous T-cell lymphomas appears to be on the rise in children and adolescents.
British study finds Roaccutane treatment causes depression-like symptoms in mice
October 3rd 2006Bath, England - In the wake of claims that severe-acne treatment Roaccutane has caused depression and suicide in patients since its introduction in 1982, researchers at the University of Bath have tested the medication and found the claims may have merit.